• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    UK Biocentre Selects the Azenta Life Sciences BioArc Ultra Automated Storage System to Advance Research Excellence

    1/23/25 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email

    BURLINGTON, Mass., Jan. 23, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has been selected as the technology provider by UK Biocentre as they expand their large-scale sample storage in support of the preservation of internationally significant sample collections. This new system is in addition to the seven Azenta BioArc™ Flex™ automated sample store systems already in place at the facility. UK Biocentre will utilize the new BioArc Ultra™ to deliver on critical research projects including the United Kingdom's largest health research program – Our Future Health.

    The BioArc Ultra will be installed into UK Biocentre's 70,000 square-foot facility in Milton Keynes, England, which specializes in the management and processing of biological samples. Currently capable of storing over 35 million samples, the facility will expand its capacity to conduct large-scale biomedical research by an additional 16 million samples with BioArc Ultra's high-density, fully automated -80°C storage system with picking capability of up to 9 million picks per year. As part of the overall solution, UK Biocentre utilizes Azenta's automated systems, as well as FluidX™ 2D-coded, high-quality screw-cap tubes, to elevate inventory management quality, reduce variability, and mitigate risk for this and other vital research projects.

    The Ultra delivers significant operational efficiency benefits, including reduced footprint, labor requirements, and electricity costs as compared to other commercially available systems, and benefits UK Biocentre's carbon emission reduction goals through the use of an eco-friendly refrigeration system with zero Ozone Depletion Potential and zero Global Warming Potential, thus advancing sustainability in science. This robust automation system offers the option of up to 10 picking stations, providing the flexibility to increase throughput and/or labware types.

    UK Biocentre will utilize the storage capacity of the BioArc Ultra in support of the UK's Our Future Health study of up to 5 million people in the development of new ways to prevent, detect, and treat diseases.

    Dr. Tony Cox OBE, Chief Executive Officer of UK Biocentre, stated, "The BioArc Ultra ensures UK Biocentre remains at the forefront of large-scale sample storage innovation while fulfilling our mission to reduce the environmental impact of vital clinical and life science research. We are proud to partner with Azenta Life Sciences to bring this unique offering to the UK, enabling us to maximize the potential of every sample."

    "We are excited to support UK Biocentre with the advanced automation sample storage capabilities of the BioArc Ultra," said Alex Esmon, Vice President and General Manager of Global Products at Azenta Life Sciences. "The addition of the BioArc Ultra delivers on the promise of enabling breakthroughs faster through substantial improvements in proven automation and refrigeration technology that ensures critical sample integrity while streamlining workflows and ensuring sustainability."

    To learn more about the BioArc Ultra, visit https://www.azenta.com/products/bioarc-ultra-high-density-80-c-automated-sample-storage-system.

    About Azenta Life Sciences

    Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research, and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

    Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

    About the UK Biocentre

    UK Biocentre is a respected leader in sample management, high-capacity bioprocessing & analysis, and automated storage. We support and facilitate large-scale biomedical, pharmaceutical, and clinical studies, enabling life-changing research in the academic, pharmaceutical and biotech communities. From the outset we've valued our role as essential collaborators in the scientific process providing reliable, high-quality solutions that help researchers make critical advancements in their fields. This drives our passion for delivering unparalleled services, using state-of-the-art technology, and adhering to the highest compliance, certification, and accreditation standards. For more information, please visit www.ukbiocentre.com.

    INVESTOR CONTACTS:

    Yvonne Perron

    Vice President, Financial, Planning & Analysis and Investor Relations

    [email protected]

    PUBLIC RELATIONS CONTACT:

    Renay Picard

    Director of Marketing, Sample Management Solutions

    [email protected]

    Azenta logo (PRNewsfoto/Azenta)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/uk-biocentre-selects-the-azenta-life-sciences-bioarc-ultra-automated-storage-system-to-advance-research-excellence-302359087.html

    SOURCE Azenta

    Get the next $AZTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    7/19/2023Mkt Perform
    Raymond James
    5/10/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    2/9/2023$65.00 → $60.00Overweight → Equal-Weight
    Stephens
    1/3/2023$60.00 → $62.00Outperform → In-line
    Evercore ISI
    3/31/2022$106.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and General Manager, Genom Zhou Ginger bought $19,132 worth of Common (417 units at $45.88), increasing direct ownership by 2% to 27,916 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/4/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • President and CEO Marotta John was granted 83,622 units of Common and bought $552,904 worth of Common (13,967 units at $39.59), increasing direct ownership by 2,982% to 100,862 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:16 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Cornog William L bought $495,000 worth of Common (12,500 units at $39.60) (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:11 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Marotta John was granted 1,000 units of Common, increasing direct ownership by 0.94% to 107,296 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      6/4/25 4:30:06 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Amendment: President and CEO Marotta John was granted 5,434 units of Common, increasing direct ownership by 5% to 106,296 units (SEC Form 4)

      4/A - Azenta, Inc. (0000933974) (Issuer)

      6/4/25 4:10:08 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Malus Alan J was granted 12,000 units of Common, increasing direct ownership by 238% to 17,035 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      6/3/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development

      Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass., May 13, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a leading artificial intelligence (AI) life sciences technology company, to enhance adeno-associated virus (AAV) gene therapy development through a fully integrated sequencing and data analysis solution. This partnership brings together GENEWIZ's industry-leading next-generation sequencing services for AAV gene therapy wi

      5/13/25 4:05:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    SEC Filings

    See more
    • SEC Form SD filed by Azenta Inc.

      SD - Azenta, Inc. (0000933974) (Filer)

      5/30/25 4:15:02 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      5/16/25 4:12:24 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form 10-Q filed by Azenta Inc.

      10-Q - Azenta, Inc. (0000933974) (Filer)

      5/9/25 4:07:49 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology